Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.

Lin Shen Ken Kato Sung-Bae KimJaffer A AjaniKuaile ZhaoZhiyong HeXinmin YuYongqian ShuQi LuoJufeng WangZhendong ChenZuoxing NiuLongzhen ZhangTienan YiJong-Mu SunJianhua ChenGuohua YuChen-Yuan Lin Hiroki HaraQing BiTaroh Satoh Roberto A Pazo-Cid Hendrick-Tobias ArkenauChristophe BorgFlorian LordickLiyun LiNingning DingAiyang TaoJingwen Shi Eric Van Cutsemnull null

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)

Tislelizumab significantly improved OS compared with chemotherapy as second-line therapy in patients with advanced or metastatic ESCC, with a tolerable safety profile. Patients with programmed death-ligand 1 TAP ≥ 10% also demonstrated statistically significant survival benefit with tislelizumab versus chemotherapy.

Keyphrases

phase iii
locally advanced
squamous cell carcinoma
small cell lung cancer
clinical trial
open label
chemotherapy induced
rectal cancer
radiation therapy
placebo controlled
replacement therapy
study protocol